illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Samsung Biologics
Company logo

Samsung Biologics | Sustainability Performance

https://samsungbiologics.com/

Engages in biopharmaceutical manufacturing and development. Operations include production of biologics, contract manufacturing, and development services for healthcare and medical industries, supporting global clients.

2011

South Korea

1,001 - 5,000 employees

Pharmaceuticals

$1B - 10B in revenue

$1B - 10B in profitability

Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.

Sustainability Ranking & Industry Benchmark

#11885
Overallⓘ
#190
in South Koreaⓘ
#278
in Pharmaceuticalsⓘ

Sustainability Maturity

ⓘ
​​0123456789​​%

Sustainability Intent

ⓘ

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

250 out of 287

Overview
Environmental
Carbon emissionsEnergy consumptionWaste ManagementWater ManagementAir & land impactNature and biodiversity
Social
Diversity and InclusionPay GapsHealth and SafetyExternalities
Governance
SDG Impact
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
Suheung

South Korea, Health Care, Pharmaceuticals


Company logo
Shinpoong Pharm

South Korea, Health Care, Pharmaceuticals


Company logo
Celltrion

South Korea, Health Care, Pharmaceuticals

CO2 scope 1 + 2 ⓘDirect emissions from owned or controlled sources, combined with indirect emissions from purchased electricity calculated using grid-average emission factors based on where the energy is consumed.
240.0KCO2e tonnes, 2024
Critical
Renewable energy ⓘProportion of the company's total energy consumption sourced from renewable sources, expressed as a percentage.
13%2024
Laggard
Waste generated ⓘTotal waste generated through the company's direct operations, including both hazardous and non-hazardous materials.
11.0Ktonnes, 2024
Laggard
Female employees ⓘProportion of women in the company's total workforce, expressed as a percentage.
46%2024
Aligned
Externalities ⓘThe monetized estimate of environmental and social impacts caused by an organization that are not reflected in its financial accounts.
15.8M$, 2024
Leading
Market cap ⓘTotal market value of the company's outstanding shares, calculated by multiplying the share price by the number of shares outstanding.
63.0T$, 2026▲16.4% YoY
Revenue ⓘTotal revenue reported in the company's financial statements for the specified reporting year, reflecting income generated from primary business activities. Expressed in millions of USD.
4.5T$, 2024▼18.8% YoY
R&D intensity ⓘResearch and development expenditure expressed as a percentage of revenue, reflecting the company's relative investment in innovation.
3.18%2024

Intensity


Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)
Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)
Energy consumption (direct) intensity (MWh /$M)
Water consumption intensity (m³ /$M)
Industry Benchmark

74.9

B/M 22.4

214.8

B/M 312.2

240.7

B/M 42.0

477.5

B/M 131.1


Powered by illuminem and GIST Impact

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
  • Samsung Biologics Co Ltd, Korean major CDMO (contract development and manufacturing organization), has faced sustained Korean FSC enforcement scrutiny over the historic 2018 KRW 4.5 trillion accounting fraud investigation (Lee Jaeyong/Cheil IndustriesSamsung C&T merger context) with Samsung Bioepis subsidiary valuation manipulation allegations affecting Korean institutional minority shareholders.
Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

image report
Available

Sustainability employees

ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.

Total sustainability employees

2-3

ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.

    Available in
    Scale package

    Access
  • Email

  • Email